The Comparative Assessment of Mycological Efficacy, Safety, Recurrence, and Cost-effectiveness of Selenium Sulfide 1.8% Shampoo Versus Ketoconazole 2% Shampoo in Pityriasis Versicolor: a Double-blind Randomized Controlled Trial

Sponsor
Indonesia University (Other)
Overall Status
Completed
CT.gov ID
NCT04007237
Collaborator
(none)
100
1
2
3.9
25.4

Study Details

Study Description

Brief Summary

There are several topical treatment for Pityriasis Versicolor including ketoconazole and selenium sulfide. Ketoconazole is a broad spectrum anti-fungal drug from imidazole group that has been reported to be effective in PV. The study aimed to reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor. A double blind randomized controlled trial was performed in patients with PV during September-December 2018. Patients who involved in this study were allocated to SeS2 or ketoconazole 2% based on block randomization. Physical examinations, scale provocation test, Wood lamp and potassium hydroxide (KOH) examination were conducted to evaluate the treatment response and side effects on 7th - 14th day. Intention to treat analysis was performed in this study. cost-effectiveness was analyzed by Incremental Cost-Effectiveness Ratio (ICER).

Condition or Disease Intervention/Treatment Phase
  • Drug: shampoo with different composition
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Masking Description:
double blind randomized clinical trial
Primary Purpose:
Treatment
Official Title:
The Comparative Assessment of Mycological Efficacy, Safety, Recurrence, and Cost-effectiveness of Selenium Sulfide 1.8% Shampoo Versus Ketoconazole 2% Shampoo in Pityriasis Versicolor: a Double-blind Randomized Controlled Trial
Actual Study Start Date :
Sep 1, 2018
Actual Primary Completion Date :
Dec 30, 2018
Actual Study Completion Date :
Dec 30, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Selsun Shampoo (SeS2 shampoo)

Subject were given the SeS2 1.8% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance

Drug: shampoo with different composition
To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.

Active Comparator: Ketoconazole shampoo

Subject were given the Ketoconazole 2% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance

Drug: shampoo with different composition
To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.

Outcome Measures

Primary Outcome Measures

  1. mycology efficacy [7 days]

    skin scrapping with KOH test 20% and Parker Blue-Black® ink with the founding of short hyphae and group spores or short hypha only as a positive result

  2. mycology efficacy [14 days]

    skin scrapping with KOH test 20% and Parker Blue-Black® ink with the founding of short hyphae and group spores or short hypha only as a positive result

  3. compliance [7 days]

    the number of day in which a participant using the shampoo which was assigned for minimum 5 days or more and the remaining volume of shampoo does not exceed 25 ml.

  4. compliance [14 days]

    the number of day in which a participant using the shampoo which was assigned for minimum 5 days or more and the remaining volume of shampoo does not exceed 25 ml.

  5. side effect [7 days]

    based on clinical symptoms : itching, burning or stinging sensation. Assessed based on patient records in the diary and through interviews during control

  6. side effect [14 days]

    based on clinical symptoms : itching, burning or stinging sensation. Assessed based on patient records in the diary and through interviews during control

  7. cost-effectiveness [two weeks]

    Cost calculations include administrative fees (registration and consultation of doctors), laboratory examinations, medical expenses and compensation for side effects adjusted for the duration of therapy. The results of the calculation of costs obtained are then linked to the negative outcome difference (KOH is still positive) or the value of absolute risk reduction (ARR) on day 14. So that cost efficacy is seen from Incremental Cost-Effectiveness Ratio

  8. recurrence [1 month]

    if the KOH test 20% give a positive result again

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Having PV characteristic skin lesions,proven by 20% KOH scraping test and Parker Blue-Black® ink, with the founding of short hyphae and group spores or short hyphae only

  • willing to participate in the study by signing the written informed consent

  • Subjects under the age of 18 with permission from parents or guardians.

Exclusion Criteria:
  • A history of hypersensitivity to the ingredients of the shampoo tested.

  • Having skin abnormalities with impaired skin integrity

  • In the treatment of topical anti-fungal therapy for less than two weeks or systemic anti-fungal for less than one month.

  • Pregnancy and breastfeeding.

  • Patients with PV lesions on the face.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Puskesmas Kecamatan Pulo Gadung Jakarta Indonesia

Sponsors and Collaborators

  • Indonesia University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fariz Nurwidya, Principal Investigator, Indonesia University
ClinicalTrials.gov Identifier:
NCT04007237
Other Study ID Numbers:
  • efficacy - PV
First Posted:
Jul 5, 2019
Last Update Posted:
Jul 5, 2019
Last Verified:
Jul 1, 2019
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Fariz Nurwidya, Principal Investigator, Indonesia University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 5, 2019